Head-to-head evidence
AFFITOPE PD01A / ACI-7104.056 vs exidavnemab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: alpha-synuclein · full Parkinson's Disease pipeline
AFFITOPE PD01A / ACI-7104.056
Developed by AC Immune
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: January 2028 · NCT06015841 (registry estimate)
exidavnemab
Developed by BioArctic AB
NCT06671938 · Phase 2 · completed
This is a randomized, double-blind, placebo-controlled trial, but it enrolled only 38 participants split across dose cohorts, its primary endpoint measures adverse-event incidence rather than efficacy, and results have not yet been posted, so no conclusion about benefit can be drawn.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AFFITOPE PD01A / ACI-7104.056's landscape · exidavnemab's landscape